Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612934 | 0.77 | — | — | |
| SCHEMBL3600173 | 0.75 | ACE (0.57) | — | |
| SCHEMBL5134719 | 0.75 | ACE (0.57) | — | |
| SCHEMBL11387242 | 0.75 | DPP4 (0.44) | DPP4 | |
| SCHEMBL11387247 | 0.75 | DPP4 (0.44) | DPP4 | |
| SCHEMBL11387250 | 0.75 | DPP4 (0.44) | DPP4 | |
| SCHEMBL4465428 | 0.74 | DPP4 (0.62) | DPP4 | |
| SCHEMBL1239549 | 0.74 | DPP4 (0.62) | DPP4 | |
| SCHEMBL719153 | 0.74 | DPP4 (0.62) | DPP4 | |
| SCHEMBL720009 | 0.74 | DPP4 (0.55) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | claimed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | claimed |
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| EP-1919864-A2 | FAP INHIBITORS | Ferring B.V. (NL) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | disclosed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | DPP4 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.